We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


KineMed, Pfizer Launch Collaboration

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "KineMed, Pfizer Launch Collaboration"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

KineMed Inc. has announced that it has entered into a strategic collaboration with Pfizer Inc. to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers.  By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.

Under the terms of the agreement, Pfizer has licensed access to the KineMed platform and rights to pursue discovery, development and potential commercialization of kinetic biomarkers in various fields. Both companies will work together on discovery research of novel biomarkers, and Pfizer will be responsible for the development and potential commercialization of any novel biomarkers or companion diagnostics for the Pfizer-selected targets.

KineMed will receive an upfront payment, as well as funding for research and development costs associated with Pfizer-selected targets. In addition, KineMed is eligible to receive development and regulatory milestone payments.

“We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology,” said Patrick Doyle, President at KineMed.